8. Additional organ-specific considerations

8.1. Cardiac allograft vasculopathy (CAV)


- Retrospective analysis of patients who received at least one drug-eluting stent for a previously untreated coronary lesion to examine the re-stenosis rates.
- Results: Drug-eluting stents have a favorable outcome when used in heart transplant patients for the treatment of CAV. Re-stenosis rates were 18%, 21%, and 26% at 6, 9 and 12 months, respectively. Predictors of re-stenosis included non-white race, ischemic etiology, intervention precipitated by symptoms and severe stenosis (≥90% stenosis) of the target lesion.


- Multicenter, randomized, controlled-trial comparing the effect of everolimus + low-dose calcineurin inhibitor + mycophenolate mofetil/azathioprine on CAV vs. standard calcineurin inhibitor + mycophenolate mofetil/azathioprine therapy.
- Results revealed no significant influence on CAV progression during the 12-month follow-up period which was assessed by intravascular ultrasound.
- However, a significant reduced rate of CAV progression was seen in patients treated with everolimus + low-dose calcineurin inhibitor + azathioprine vs. standard calcineurin inhibitor + azathioprine. On the other hand, an accelerated rate of CAV progression was seen among patients treated with everolimus + low-dose calcineurin inhibitor + mycophenolate mofetil vs. standard calcineurin inhibitor + mycophenolate mofetil.


- Guidelines published by ISHLT on the care of heart transplant patients.
- Specific pages: 934 and 935 – outlines recommendations on the diagnosis and management of cardiac allograft vasculopathy; 942 – outlines recommendations on re-transplantation.


- Randomized, prospective, multicenter study comparing the efficacy, safety and incidence of CAV in de novo heart transplant patients receiving everolimus (1.5 mg/day with goal trough 3-8 ng/mL or 3 mg/day with goal trough 6-12 ng/mL in divided doses) with reduced-dose cyclosporine vs. mycophenolate mofetil with full-dose cyclosporine (intervention initiated within 72 hours of transplantation).
- Results: Everolimus at a target concentration of 3-8 ng/mL had the following outcomes: noninferior to mycophenolate mofetil for the composite outcome of biopsy-proven acute rejection of ISHLT grade 1, acute rejection with hemodynamic compromise, graft loss/re-transplantation, death, or loss to follow-up at 12 months and was maintained at month 24; significantly reduced intimal proliferation on blinded IVUS assessment and significantly less patients diagnosed with CAV during the first year post-transplant. There was a higher mortality rate in patients receiving everolimus 3 mg (target 6–12 ng/mL), leading to discontinuation of recruitment to this treatment arm.

- Randomized, double-blind, prospective trial comparing everolimus + cyclosporine + corticosteroids with azathioprine + cyclosporine + corticosteroids in recipients of a first heart transplant. Interventions were initiated within 72 hours after transplant.
- Results: Both 1.5 mg/day and 3 mg/day of everolimus administered in combination with cyclosporine and corticosteroids were superior to azathioprine + cyclosporine + corticosteroids in preventing the primary efficacy endpoint (death, graft loss or a second transplantation, or biopsy-proven rejection) at 6 months. Average increase in the maximal intimal thickness and incidence of CAV was significantly less in both everolimus groups compared to azathioprine containing group.


- Randomized, open-label study comparing sirolimus with azathioprine in combination with cyclosporine and steroids at the time of transplant on acute cellular rejection and graft vasculopathy in heart transplant.
- Results: Sirolimus used from the time of transplant markedly reduced the proportion of patients experiencing acute rejection (32.4% 3 mg/day sirolimus vs. 56.8% azathioprine; p=0.027) with comparable patient survival at a dose of 3 mg/day. At 6 months and 2 years, patients on azathioprine had significantly increased measurements of all CAV parameters (mean and maximal intima+media thickness) and a significantly higher incidence of CAV compared to sirolimus.


- Prospective, randomized, open-label trial assessing the effect of pravastatin on cholesterol lowering, rejection, survival, and the development of coronary vasculopathy in heart transplant patients.
- Results: Pravastatin (doses of 40 mg/day) lowers cholesterol levels; reduces the incidence of cardiac rejection with hemodynamic compromise, thereby increasing first-year survival (95% vs. 81 %; p=0.037); and reduces the development of coronary vasculopathy (3 pts vs. 10 pts; p=0.049).


- Results: The use of pravastatin in heart transplant patients maintains survival benefit and appears to reduce the development of CAV. Increased 10-year survival with the pravastatin group (68% pravastatin vs. 48% control; p=0.026). 10-year freedom from angiographic CAV and/or death was greater in the pravastatin group (43% vs. 20%; p=0.009).

- Multicenter study to assess the validity of first-year IVUS data as a surrogate marker for long-term outcome after heart transplantation. First-year IVUS results and subsequent five-year clinical follow-up data were reviewed in 125 heart transplant patients. The change in maximal intimal thickness (MIT) from baseline to one-year was recorded into two groups: those with ≥0.5 mm (group 1) and those with MIT <0.5 mm (group 2).
- Results: Group 1 compared to group 2 had a higher incidence of death or graft loss (20.8% vs. 5.9%, p=0.007), had more nonfatal major adverse cardiac events and/or death or graft loss (45.8% vs. 16.8%; p=0.003), and had more findings of newly occurring angiographic luminal irregularities (65.2% vs. 32.6%, p=0.004).
- This study suggests that progression of intimal thickening ≥0.5 mm in the first year after transplantation appears to be a reliable surrogate marker for subsequent mortality, nonfatal major adverse cardiac events, and development of angiographic CAV through 5 years after heart transplant.


- Open-label, prospective, randomized study investigating the efficacy of rapamycin in preventing disease progression in patients with angiographically documented transplantation vasculopathy versus standard care (calcineurin inhibitor, antiproliferative, and steroids).
- The primary end point was a composite of clinically significant events including death, acute myocardial infarction, need for angioplasty or bypass surgery and/or a >25% increase in the catheterization score.
- Results: In the rapamycin group, 3/22 patients reached primary end points versus 14/24 patients in the control group (P<0.001). Rapamycin effectively slowed the progression of graft vasculopathy and reduced the incidence of clinically significant cardiac events.


- A review of available literature on the prevention and treatment options of CAV.


- Clinical consensus guidelines derived from critical analysis of available literature pertaining to angiography, intravascular ultrasound imaging, non-invasive imaging tests, and gene-based and protein-based biomarkers for standardizing the nomenclature for CAV.


- Retrospective analysis of sirolimus with calcineurin inhibitor withdrawal vs. continued calcineurin inhibitor therapy for the long-term attenuation of CAV progression and effects on cardiac-related morbidity and mortality. The time from transplant to conversion to sirolimus and calcineurin inhibitor withdrawal ranged from 0.2-9 years.
- Results: Substituting calcineurin inhibitor with sirolimus <2 years post-transplant resulted in a delay in progression of plaque volume and a delay in progression of plaque index. Those converted to sirolimus >2 years post-transplant had a significant increase in vessel volume, resulting in a delay in progression of plaque index as well. Five year survival and freedom from cardiac-related events was significantly improved in those on sirolimus.

- Retrospective analysis of consecutive cardiac transplantation patients at a single-center who received a drug-eluting (DES) vs. bare-metal stent (BMS) for de novo cardiac allograft vasculopathy from 1997-2009. Angiographic and clinical outcomes were subsequently evaluated at 1 year.
- Results: At the 12-month angiographic follow-up visit, the mean lumen loss was significantly lower in the DES group vs. BMS group (0.19± 0.73 mm vs 0.76± 0.97 mm, p=0.02). The DES group had a lower rate of in-stent restenosis (12.5% vs. 33%, p=0.18) as well as a significantly lower rate of target lesion revascularization (0% vs. 19%, p=0.03). Additionally, at one year DESs were associated with a lower composite rate of cardiac death and nonfatal MI (12% vs. 38%, p=0.04).
- Conclusion: DESs are safe and effective in the suppression of neointimal hyperplasia after PCI for CAV, resulting in significantly lower rates of late lumen loss and target lesion revascularization, as well as a reduced combined rate of cardiac death and nonfatal MI.


- Prospective, randomized, unmasked study comparing the efficacy of simvastatin (started on POD#4) with dietary therapy alone. After 4 years, most patients in both groups received statins due to improved survival and lower incidence of transplant vasculopathy.
- Results: At 8 years, survival rates were 88.6% in simvastatin group vs. 59.5% in control group (p<0.006). Incidence of transplant vasculopathy confirmed by angiography was 24.4% in the simvastatin group vs. 54.7% in the control group (p<0.02).


- Patients were randomized to control (n = 13) or to 10 to 20 mg of atorvastatin (n = 12). Four patients in the control group had an LDL > 130 mg/dl and niacin was given.
- At the 1 year intracoronary ultrasonography, patients taking atorvastatin showed a decrease in new or progressing lesions (2.5 ± 1.7 vs. 4.2 ± 1.8 lesions/patient, p = 0.02), progression of maximal intimal thickness (0.12 ± 0.07 vs. 0.52 ± 0.17 mm, p = 0.04), and percent area stenosis (5.9 ± 2.2% vs. 19.0 ± 5.5%, p = 0.04).
- Atorvastatin administered to patients with normal or mild hypercholesterolemia in the initial year after transplant reduced the initial increase in LDL cholesterol. This in turn prevented the development and progression of coronary artery lesions and endothelial dysfunction with only mild long-term decreases in cholesterol levels.


- A review of the literature regarding medication management of CAV was conducted via a search of the MEDLINE database. Studies were included if they were published in English, conducted in humans ≥ 18 years of age or older, and used noninvestigational medications.
- Immunosuppressive medications such as the antiproliferative mycophenolate, the calcineurin inhibitor tacrolimus, and the proliferation signal inhibitors sirolimus and everolimus have been shown to prevent the development of CAV.
- Certain cardiovascular medications, such as HMG-CoA reductase inhibitors (statins), gemfibrozil, calcium channel blockers, and angiotensin-converting enzyme inhibitors, have also demonstrated efficacy.
- Prevention of CAV has also been observed with prophylaxis against cytomegalovirus infection and antioxidant medications. Despite being commonly used in heart transplant patients, neither
antiplatelet agents nor glycemic control have proved effective at preventing CAV. Only sirolimus has been shown to arrest the progress of existing CAV.


- A 12-month, open-label, multicenter, randomized, controlled Scandinavian study, in which adult de novo heart transplant recipients (n = 115) were randomized to everolimus (3-6 ng/mL) with reduced-exposure calcineurin inhibitor (CNI; cyclosporine) to weeks 7-11 after transplant, followed by increased everolimus exposure (target 6-10 ng/mL) with cyclosporine withdrawal or standard-exposure cyclosporine. All patients received mycophenolate mofetil and corticosteroids.
- Ninety-five (83%) patients had matched intravascular ultrasound examinations at baseline and 12 months. Mean (± SD) recipient age was 49.9 ± 13.1 years.
- The everolimus group (n = 47) demonstrated significantly reduced CAV progression as compared to the calcineurin inhibitor group (n = 48) (ΔMaximal Intimal Thickness 0.03 ± 0.06 and 0.08 ± 0.12 mm, ΔPercent Atheroma Volume 1.3 ± 2.3 and 4.2 ± 5.0%, ΔTotal Atheroma Volume 1.1 ± 19.2 mm³ and 13.8 ± 28.0 mm³ [all p-values ≤ 0.01]).
- Everolimus patients also had a significantly greater decline in levels of soluble tumor necrosis factor receptor-1 as compared to the calcineurin inhibitor group (p = 0.02).


- A total of 110 of 115 patients completed the 12-month SCHEDULE study as described above and 102 attended a follow-up visit at month 36.
- Coronary intravascular ultrasound at 36 months revealed significantly reduced progression of allograft vasculopathy in the everolimus group compared with the CNI group, as defined by a significantly lower mean increase in maximal intimal thickness from week 7-11 (p=0.019).
- Biopsy-proven acute rejection grade ≥2R occurred in 10.2% and 5.9% of everolimus- and calcineurin inhibitor-treated patients, respectively, during months 12-36. Serious adverse events occurred in 37.3% and 19.6% of everolimus- and calcineurin inhibitor-treated patients, respectively (p = 0.078).


- Retrospective review of 63 heart transplant recipients who survived at least 1 year after heart transplant. Twenty-four recipients were converted from mycophenolate mofetil (MMF) to everolimus (EVL) (EVL group, 2.2 ± 2.3 years after heart transplant), while 39 recipients were maintained on MMF (MMF group, 2.4 ± 2.2 years after heart transplant). The EVL group underwent three-dimensional intravascular ultrasound analysis before and 1 year after conversion to EVL and these data were compared with data from 2 consecutive IVUS in the MMF group.
- IVUS indices in the EVL group at 1 year after conversion did not show increased CAV development, whereas a significant increase in %plaque volume (p=0.006) and decrease in lumen volume (p=0.001) were observed in the MMF group. EVL conversion was significantly associated with smaller increases in %plaque volume (p=0.004) and smaller decreases in lumen volume (p=0.017). IVUS indices in the late EVL conversion group (≥ 2 years) also did not exhibit increased CAV development while those in the MMF group did.

- Prospective, observational cohort study with 143 heart transplant recipients. The early cohort included 91 patients with baseline (within 6 weeks of transplant) and 1 year follow-up IVUS study. The late cohort included 52 patients with 1 year and 5 year IVUS studies. Patients received either everolimus + cyclosporine + steroids vs. cyclosporine + mycophenolate mofetil + steroids.
- In the early cohort, patients could be started on everolimus (goal trough 3-8 ng/ml) within a few days after transplant or after 2-6 weeks of mycophenolate mofetil therapy post-transplant in combination with cyclosporine. In the late cohort, patients could switch from mycophenolate mofetil/azathioprine to everolimus in combination with cyclosporine after the year 1 IVUS.
- In the early cohort, everolimus independently reduced the odds for early CAV (0.14 [0.01–0.77]; p = 0.02). However, everolimus did not influence late CAV progression.


- This review discusses the currently available drugs for CAV, the evidence behind their use, and future targets of therapy.


- Retrospective study of 206 heart transplant patients to evaluate the association between early aspirin therapy and long-term risk of CAV.
- Early aspirin use was associated with a statistically significant reduction in CAV risk of 84%.


- This literature review focuses on risk factors and pathophysiology of CAV, treatment options, and specifically the role of statin therapy at varying intensity levels.


- Retrospective study of heart transplant patients between 2010 and 2012 who received either induction with antithymocyte globulin or no induction therapy. Primary endpoints were first year plaque progression and incidence of rapid plaque progression.
- Overall CAV progression was slower in those patients who received induction with antithymocyte globulin in terms of maximal intimal thickness, maximal percent stenosis, and plaque volume on IVUS.


- Heart transplant recipients between 1998 and 2005 were randomized to two groups: low dose tacrolimus with sirolimus or tacrolimus with mycophenolate mofetil. At 8 years there was no statistically significant difference in number of acute rejection episodes, survival, or CAV.
- Freedom from CAV grade 1 or higher was 55.4% in the low dose tacrolimus/sirolimus group compared to 60% in the tacrolimus/mycophenolate mofetil group.
8.2. Cardiovascular risk management


- Guidelines published by the AHA and ACC on lifestyle modifications related to diet and physical activity to reduce CV risk in adults.


- Guidelines published by the AHA and ACC on the management of high blood pressure in adults.
- Includes section specific to renal transplant recipients.


- Retrospective analysis of patients who received kidney transplant from 1993-2003 investigating whether long-term graft survival was improved in patients who received long-term ACE-I/ARB or CCB for at least two years.
- Patients were stratified based on their blood pressure one-year after transplant as controlled (<130/80 mmHg) or uncontrolled (>130/80 mmHg) and according to the antihypertensive medication taken (ACE-I/ARB or CCB).
- Results: Graft survival was longer in the controlled group than in the non-controlled group (p<0.05). Graft survival was longer in patients who received long-term treatment with ACE-I/ARB, CCB, or combination of ACE-I/ARB and CCB (p<0.001).
  - The benefits of ACE-I/ARB therapy were more pronounced in the non-controlled group compared to the controlled group.
  - As seen in previous studies, CNI treated kidney transplant recipients benefit from CCB treatment.

- Conclusion: Long-term ACE-I/ARB and CCB therapy is beneficial for graft survival, especially in patients with diabetes and/or albuminuria.


- Randomized, double-blind, placebo-controlled trial of patients receiving cyclosporine based immunosuppression followed for 5-6 years in the primary study. This was an open-label 2-year extension study of fluvastatin 80 mg/day.
  - Dose increased to fluvastatin 40 mg twice daily after two years due to landmark trials indicating a relationship between LDL concentrations and decreasing CV events.
  - Primary endpoint was time to first major adverse cardiac event (MACE) [defined as cardiac death, non-fatal MI, and cardiac intervention procedures].
  - Secondary endpoints included: cardiac death or non-fatal MI, renal graft loss, individual cardiac events, and all-cause mortality.
- Results: Patients randomized to fluvastatin had a reduced risk of MACE (HR 0.79, p=0.036) and a 29% reduction in cardiac death or definite non-fatal MI (HR 0.71, p=0.014). Total mortality and graft loss did not differ between groups.
- Conclusion: Fluvastatin produces a safe and effective reduction in LDL with reduced risk of MACE in kidney transplant recipients.

- Retrospective, observational, multi-center study comparing traditional and non-traditional CHD risk factors. Additionally, the PORT investigators developed risk-prediction equations for kidney transplant in standard clinical practice.
- 23,575 kidney transplant patients were included from 14 centers worldwide.
- Results: CHD cumulative incidence was 3.1%, 5.2%, and 7.6% at 1, 3, and 5 years post-transplant, respectively.
- They identified transplant-related risk factors: pre-transplant diabetes, new onset post-transplant diabetes, prior pre- and post-transplant CV events, estimated GFR, delayed graft function, acute rejection, age, sex, race, and duration of pre-transplant ESRD.
- The risk-prediction equations performed well, with the time-dependent c-statistic greater than 0.75.
- Conclusion: transplant-related risk factors, especially those linked to graft function, explain the variation seen in CHD after kidney transplant.


- Randomized, double-blind, parallel-group study that compared fluvastatin (Lescol) with placebo followed up for a minimum of 5 years and maximum of 6 years.
- Patients were adult renal transplant recipients who had received a transplant at least 6 months previously and whose graft function was stable. All patients received cyclosporine-based immunosuppression and no patient was administered statins before recruitment.
- Results: Pre-existing coronary heart disease (HR 3.69; p<0.001), total cholesterol level (HR, 1.55 per 50 mg/dL; p=0.0045), and prior acute rejection (HR, 2.36; p=0.0023) were independent risk factors. Independent risk factors for cardiac death were age, diabetes, ST-T changes on the ECG, and serum creatinine level.


- Specific guidelines on different topics pertaining to kidney transplant with subsequent literature references and treatment options for kidney transplant recipients. Additionally, specific guidelines on monitoring are provided.
- Chapter 16: Hypertension, Dyslipidemias, Tobacco Use, and Obesity
- Chapter 17: Cardiovascular disease management
- Meta-analysis of randomized controlled trials comparing maintenance steroid group with complete avoidance or withdrawal of steroids.
- Results: Steroid avoidance or withdrawal was associated with significantly increased risk of acute rejection over maintenance steroids (RR 1.56, p<0.0001). No significant differences seen among the groups in corticosteroid resistant acute rejection, patient survival, or graft survival. Cardiovascular risk factors including hypertension (RR 0.90, p<0.0001), new onset diabetes (RR 0.64, p=0.0006), and hypercholesterolemia (RR 0.76, p<0.0001) were reduced significantly by steroid avoidance or withdrawal.
- Conclusion: There were significant benefits in cardiovascular risk profiles with steroid avoidance or withdrawal, however with an increase in risk of acute rejection. In addition, there was no difference on graft function, or graft and patient survival between the groups.

- A review article that compares the mechanism and intensity by which individual immunosuppressive agents may affect cardiovascular risk factors (hypertension, diabetes, dyslipidemias, etc.) potentially allowing practitioners to design strategies or tailor maintenance immunosuppression for individual patients.

- A review that focuses on both traditional and novel cardiovascular risk factors and also on both primary and secondary preventative strategies that are available for the management of post-transplant CVD in renal transplant patients.
- Risk factors that are mentioned in this review include: hypertension, diabetes mellitus, dyslipidemias, obesity, tobacco use, left ventricular hypertrophy, and anemia.

Pham PT, Pham PC, Danovitch GM. Cardiovascular disease post-transplant. Semin Nephrol. 2007; 27(4): 430-44.
- A review of post-transplant complications associated with increased morbidity and mortality after renal transplantation. Also provided are conventional and unconventional cardiovascular risk factors after renal transplant and an approach to their medical management.

- A review article on the diagnosis, management, and consequences of obesity, diabetes, dyslipidemia, hypertension post-liver transplant.

- Prospective, multicenter, randomized, double-blind, placebo controlled trial in which 96 heart transplant patients were randomized to receive ramipril or placebo therapy within 8 weeks post-transplant.
- Plaque volumes at 1 year were similar between the ramipril and placebo groups (162.1 ± 70.5 mm$^3$ vs. 177.3 ± 94.3 mm$^3$, respectively; p = 0.73). Patients receiving ramipril had improvement in microvascular function as shown by a significant decrease in the index of microcirculatory resistance (IMR) (21.4 ± 14.7 to 14.4 ± 6.3; p = 0.001) and increase in coronary flow reserve (3.8 ± 1.7 to 4.8 ± 1.5; p = 0.017), from baseline to 1 year. This did not occur with IMR in the placebo-treated patients.
- Ramipril stabilized the levels of endothelial progenitor cells and improves microvascular function, which has been associated with long term survival after heart transplant.


- Guidelines published by the ACC and AHA on the treatment of cholesterol to reduce CV risk in adults.


- Studied 115 kidney transplant recipients that were treated with mTOR inhibitor plus steroids compared to a control group of 58 kidney transplant recipients who received calcineurin inhibitor, mycophenolate mofetil or sodium and steroids.
- Results: mTOR inhibitor group showed higher mean levels of total cholesterol (249 vs. 204.6 mg/dL, p<0.0001) and LDL (136.5 vs. 117.7 mg/dL, p=0.015), as well as triglycerides (202 vs. 142 mg/dL; p<0.0001). Mean eGFR was lower in the mTOR inhibitor group vs. control (42.9 vs. 51.9; p=0.0003). Incidence of coronary artery disease was higher among patients treated with mTOR inhibitors than control (p=0.04).
- CVD, defined as MI, PCI, stroke, aortic aneurysm, PE, sudden cardiac death appeared in 26 patients in mTOR inhibitor group vs. 4 patients in control group (p=0.24).
- Conclusions: No real correlation of increased incidence of CVD among the patients on mTOR inhibitor vs. control, although there was a higher burden of cardiovascular risk factors in that group. More studies needed for confirmation.


- Post hoc analysis of FAVORIT a multicenter, double-blind, randomized, controlled clinical trial to determine whether lowering homocysteine levels with vitamin therapy reduces the rate of arteriosclerotic CVD outcomes.
- Results: In 3676 participants with complete data, there were 527 CVD events over 3.8 years. Each 5 ml/min/1.73 m$^3$ higher eGFR at levels below 45 ml/min/1.73 m$^3$ was associated with a 15% lower risk of both CVD (HR = 0.85) and death (HR = 0.85), while there was no association between eGFR and outcomes at levels above 45 ml/min/1.73 m$^3$.
- Conclusion: In stable kidney transplant recipients, lower eGFR is independently associated with adverse events, suggesting that reduced kidney function itself rather than pre-existing co-morbidity may lead to CVD.

- A review article of all the pertinent studies involving the conversion of calcineurin inhibitor based maintenance immunosuppression to mTOR inhibitors and the potential to reduce cardiovascular disease following kidney transplantation.


- Retrospective review of 964 pediatric (ages 5 to 18 years) heart transplant recipients in the multicenter Pediatric Heart Transplant Study registry from 2001 to 2012. Patients were excluded if they were undergoing re-transplantation, survived <1 year post-transplant, or had missing data regarding statin use. The effects of statins beyond the first year were estimated by Kaplan-Meier and Cox regression multivariable analysis for freedom from PTLD, rejection requiring treatment, any severity of CAV, and survival.

- Statin use was variable among participating centers with only 30% to 35% of patients ≥10 years of age started on a statin at <1 year post-transplant. After the first year post-transplant, statin-treated children (average age at transplant 13.24 ± 3.29 years) had significantly earlier rejection (HR 1.42, 95% CI 1.11 to 1.82, p = 0.006) compared with untreated children (transplanted at 12 ± 3.64 years) after adjusting for conventional risk factors for rejection. Freedom from PTLD, CAV and overall survival up to 5 years post-transplant were not affected by statin use, although the number of events was small.


- Data was derived from randomized controlled trials and quasi-randomized controlled trials. It was found that statins may reduce major cardiovascular events (1 study, 2102 participants: RR 0.84, CI 0.66 to 1.06), cardiovascular mortality (4 studies, 2322 participants: RR 0.68, CI 0.45 to 1.01), and fatal or non-fatal myocardial infarction (1 study, 2102 participants: RR 0.70, CI 0.48 to 1.01); although effect estimates lack precision and include the possibility of no effect.

- Statins had uncertain effects on all-cause mortality (6 studies, 2760 participants: RR 1.08, CI 0.63 to 1.83); fatal or non-fatal stroke (1 study, 2102 participants: RR 1.18, CI 0.85 to 1.63); creatine kinase elevation (3 studies, 2233 participants: RR 0.86, CI 0.39 to 1.89); liver enzyme elevation (4 studies, 608 participants: RR 0.62, CI 0.33 to 1.19); withdrawal due to adverse events (9 studies, 2810 participants: RR 0.89, CI 0.74 to 1.06); and cancer (1 study, 2094 participants: RR 0.94, CI 0.82 to 1.07).

- Statins significantly reduced serum total cholesterol (12 studies, 3070 participants: MD -42.43 mg/dL, CI -51.22 to -33.65); low-density lipoprotein cholesterol (11 studies, 3004 participants: MD -43.19 mg/dL, CI -52.59 to -33.78); serum triglycerides (11 studies, 3012 participants: MD -27.28 mg/dL, CI -34.29 to -20.27); and lowered high-density lipoprotein cholesterol (11 studies, 3005 participants: MD -5.69 mg/dL, CI -10.35 to -1.03).

- Statins may reduce cardiovascular events in kidney transplant recipients, although treatment effects are imprecise. Statin treatment has uncertain effects on overall mortality, stroke, kidney function, and toxicity outcomes in kidney transplant recipients. Additional studies would improve our confidence in the treatment benefits and harms of statins on cardiovascular events in this clinical setting.

- Retrospective study that investigated the use of PCSK9 inhibitors in heart transplant recipients with intolerance to statins or need for additional cholesterol reduction, as well as evidence of cardiac allograft vasculopathy.
- Ten patients were treated with either evolocumab or alirocumab for an average of 296 ± 125 days. A statistically significant reduction in total cholesterol (281±52 mg/dl to 197±36 mg/dl; p = 0.002) and LDL cholesterol (170±22 mg/dl to 101±39 mg/dl; p = 0.001) was observed. No episodes of cardiac rejection, impact on ejection fraction, increased hospitalizations, or increased infections was observed.


- Overview of major cardiovascular risk factors in solid organ transplant including metabolic syndrome, post-transplant diabetes, hypertension, tobacco use, and obesity.


- A review of cardiovascular risk after solid organ transplant, donor and recipient risk factors, prevention and treatment strategies, as well as final recommendations on management.

8.3. New onset diabetes mellitus after transplantation


- A review article on NODAT including diagnostic criteria, incidence after solid organ transplant, suggested risk factors and potential mechanisms as well as management.


- Pre-existing diabetes is a major concern in renal transplant patients. It can serve as a predictor for mortality and rejection during the first year.


- Recommendations include: terminology revision from new-onset diabetes after transplantation to post-transplantation diabetes mellitus (PTDM), exclusion of transient post-transplant hyperglycemia from PTDM diagnosis, expansion of screening strategies (incorporating postprandial glucose and HbA1c) and opinion-based guidance regarding pharmacological therapy in light of recent clinical evidence.

- New onset diabetes after transplantation guidelines.


- Review article explaining suggested approaches to treating patients with new onset diabetes.


- ADVANCE (NCT01304836) was a phase 4, multicenter, prospectively randomized, open-label, 24-week study comparing the incidence of post-transplantation diabetes mellitus (PTDM) with 2 prolonged-release tacrolimus corticosteroid minimization regimens.
- The full-analysis set included 1081 patients (arm 1: n = 528, arm 2: n = 553).
- Week 24 Kaplan-Meier estimates of PTDM were similar for arm 1 versus arm 2 (17.4% vs 16.6%; P = 0.579).
- Incidence of composite efficacy failure, graft and patient survival, and mean estimated glomerular filtration rate were also comparable between arms.
- Biopsy-proven acute rejection and acute rejection were significantly higher in arm 2 versus arm 1 (13.6% vs 8.7%, P = 0.006 and 25.9% vs 18.2%, P = 0.001, respectively).
- Tolerability profiles were comparable between arms.


- Review article highlighting the risk factors for NODAT as well as management of care.


- Review article discussing management of post-transplant diabetes.


- Study done using the OPTN/UNOS database to identify risk factors associated with the development of NODAT.


- Evaluating cumulative evidence for SNPs associated with NODAT in kidney transplant recipients has revealed three SNPs associated with NODAT. An adequately powered, dense genome-wide association study will provide more information using a carefully defined NODAT phenotype.


• This study demonstrated that liver transplant recipients with hepatitis C virus have a higher incidence and more risk factors for NODAT compared with non-HCV recipients.


• This review discusses the diagnosis of NODAT based on latest consensus guidelines, contributing factors, and how various screening practices and guidelines affect our knowledge of the epidemiology.


• This study in 167 kidney transplant recipients identified vitamin D deficiency, proteinuria, and hyperphosphatemia as independent risk factors for NODAT. Paricalcitol was identified as a protective factor for NODAT.


• This retrospective study determined acute rejection, older age, higher Charlson Comorbidity Index, and BMI as independent risk factors for NODAT in kidney transplant recipients.


• DIRECT (Diabetes Incidence after Renal Transplantation: Neoral C(2) Monitoring Versus Tacrolimus) was a 6-month, open-label, randomized, multicenter study which used American Diabetes Association/World Health Organization criteria to define glucose abnormalities. De novo renal transplant patients were randomized to cyclosporine microemulsion (CsA-ME, using C(2) monitoring) or tacrolimus, with mycophenolic acid, steroids and basiliximab. The intent-to-treat population comprised 682 patients (336 CsA-ME, 346 tacrolimus)

• Results: NODAT or impaired fasting glucose (IFG) at 6 months, occurred in 73 CsA-ME patients (26.0%) and 96 tacrolimus patients (33.6%, p = 0.046).

• BPAR, graft loss or death at 6 months, occurred in 43 CsA-ME patients (12.8%) and 34 tacrolimus patients (9.8%, p = 0.211).

• Mean glomerular filtration rate (Cockcroft-Gault) was 63.6 +/- 20.7 mL/min/1.73 m(2) in the CsA-ME cohort and 65.9 +/- 23.1 mL/min/1.73 m(2) with tacrolimus (p = 0.285); mean serum creatinine was 139 +/- 58 and 133 +/- 57 mmol/L, respectively (p = 0.005).

• Blood pressure was similar between treatment groups at month 6, but total cholesterol, LDL-cholesterol and triglyceride levels were significantly higher with CsA than with tacrolimus (total cholesterol:HDL remained unchanged).

• The profile and incidence of adverse events were similar between treatments.


• Prospective, multi-centre, controlled, randomized, parallel group, open-label study involving kidney transplant patients, comparing a steroid-free immunosuppressive protocol (low-dose tacrolimus and MMF with ATG induction) with low-dose tacrolimus, MMF and steroids with anti IL2-R induction.
The primary objective of the study is to assess the cumulative incidence of NODAT in the two study arms 12 months after transplantation using the American Diabetes Association type 2 diabetes diagnostic criteria.


• Review of diabetes after transplant, modifiable and non-modifiable risk factors, and treatment options.


• This is a review of PTDM and current management strategies, including a review of newer classes of treatment such as SGLT2 inhibitors, GLP1 agonists and DPP-4 inhibitors


• Review of the literature related to dietary interventions and post-transplant metabolic complications, including dyslipidemia, diabetes, and obesity.

8.4. Biliary complications and management


• Review of endoscopic options for diagnosis and management of biliary complications, including comparison of MRCP and ERCP and discussion of newer accessory devices.


• Graft and patient survival were significantly reduced in liver retransplant patients who had biliary complications, compared to those without biliary complications.


• Single center, retrospective review of patients with ductopenic rejection (DR) to identify risk factors. Incidence of hepatitis C infection was significantly higher in patients with DR than in those without DR.


• Report on the management of post-liver transplant bile duct loss from a single center. Bile duct loss was associated with chronic allograft rejection.


• Review of biliary complications including etiology and management.

- Comprehensive review of biliary complications post-liver transplant, including etiology, diagnosis and interventions.

- Review of management of biliary strictures post-liver transplant, with a focus on endoscopic and surgical techniques.

- Single center retrospective analysis of etiology, risk factors, management, and outcomes of patients biliary cast syndrome post-liver transplant. Hepatic artery stenosis, biliary strictures and renal replacement therapy were identified as risk factors.

- Comparison of incidence of biliary complications in living and deceased donor liver transplant. Complications are more common in living donor liver transplantation, but management is similar.

- This article is a review of the treatment of biliary complications after liver transplant.

- This study identified older age and lower Child score as independent risk factors for prevalence of gallstones among liver transplant recipients.

- This study included liver transplant patients between 2005 and 2013 at a single center. Of the total population, 17.8% developed biliary complications, with the majority being biliary stenosis. There was no statistically significant difference in patient or graft survival. Patient at higher risk of complications included those with AB blood type, viral hepatitis and alcoholic cirrhosis.

- Retrospective study comparing ever smokers and never smokers and overall biliary complication rate. Biliary complications included strictures, leaks, or bilomas requiring intervention. Positive smoking history at time of transplant was a predictor of biliary complication, while increased time from quit date to transplant was a protective factor.

- Radioembolization for hepatocellular carcinoma pre-transplant was associated with decreased odds of biliary complications post-transplant with no statistically significant difference in hepatic artery complications.


- Retrospective review of hepatocellular carcinoma patients who received TACE before liver transplantation. The study found that these patients had increased risk of hepatic artery complications, but similar rates of biliary complications.

8.5. Calcineurin inhibitor neurotoxicity


- Case report of bilateral lung transplant recipient that developed posterior reversible encephalopathy syndrome 6 months post-transplant. She was successfully managed by reducing tacrolimus exposure through use of an alternative regimen of sirolimus combined with reduced-dose tacrolimus.
- Titrated the tacrolimus and sirolimus dose for a combined goal level of 10-20 ng/mL (adding tacrolimus and sirolimus levels together)


- Review of mechanisms and manifestations of CNI-induced neurotoxicity.


- Case report of a pediatric renal transplant patient (11 year old girl) who experienced tacrolimus-induced neurotoxicity on post-operative day 12.
- Tacrolimus level was measured at 19.7 ng/mL at the time of symptom appearance. The patient was initially managed with tacrolimus dose adjustments to target a level of 5-10 ng/mL. Full reversal of symptoms was achieved when tacrolimus was changed to cyclosporine.


- Retrospective analysis of 7 patients with presumed tacrolimus-induced encephalopathy (N= 4 post-liver transplant, N=3 bone marrow transplant). FLAIR was specified as the optimal MRI sequence over DWI to recognize tacrolimus encephalopathy. It was also noted that 5 of 6 patients with clinical data available had sudden electrolyte or fluid changes prior to onset of CNS disturbances.


- This study analyzed 85 OLT patients at 10-years post-transplant using cerebral MRIs and psychometric testing. Patients receiving CNI showed significantly worse visuospatial/constructional ability compared with controls (P≤0.04). Patients on low-dose CNI therapy had overall impaired cognitive function
compared with controls (p=0.01). Total tacrolimus dose and mean trough level were negatively correlated to cognitive function. Lastly, patients treated with CNI therapy had more white matter hyperintensities than patients on CNI-free therapy (p<0.05). These effects were seen especially in patients already experiencing nephrotoxic side effects.

- Low-dose CNI therapy: tacrolimus < 5 ug/L or cyclosporine < 50 ug/L
- Standard-dose CNI therapy: tacrolimus > 5ug/L or cyclosporine >50 ug/L


- Case report of a 51 year old woman post OLT who developed signs of Parkinsonism with progressive worsening neuropsychiatric symptoms associated with tremors


- Case report of a 21 year old woman post living donor kidney transplant from her mother
- Patient developed neurological deficits within the 1st day of tacrolimus initiation and had a gangliocytoma which could possibly cause CNI-induced neurotoxicity in the early postoperative period

### 8.6. Chronic allograft nephropathy


- The authors provided a review of the importance of calcineurin inhibitor toxicity in chronic allograft dysfunction.


- This article describes the incidence, nature, pathology, and diagnostic approaches of chronic allograft nephropathy
- Transplant glomerulopathy is a manifestation of chronic AMR against the kidney allograft


- 315 kidney transplant recipients prospectively enrolled at the time of an indication based biopsy to assess cause of allograft dysfunction; range of 6 days to 32 years post-transplant
- 60 kidney transplants lead to graft failure during the follow-up period with a majority attributed to antibody mediated rejection (ABMR) or mixed rejection
- 18 of 19 patients with documented nonadherence at time of biopsy had evidence of ABMR
- 3 groups of nonrejection causes of failure: glomerulonephritis, polyomavirus nephropathy, and failure in context of an concurrent illness


- This retrospective trial identifies the determinants associated with graft outcome in transplant glomerulopathy.

- This trial details the relative importance of non-HLA antibodies to the development of transplant glomerulopathy using microarrays.
- Highlights the strengths and limitations of large throughput protein microarray screening can be informative but has high false-positive rates


- This study describes the histologic changes of renal allografts using protocol biopsies at 1 and 5 years post-transplant and highlights the importance of graft injury to development of chronic changes.


- This review discusses risk factors for the deterioration of the kidney allograft function, and highlights caveats in current monitoring leading to chronic changes while suggesting avenues to decrease incidence of chronic allograft nephropathy.
- Calcineurin inhibitor withdrawal may be one of the most important opportunities for consideration, both in patients with established allograft nephropathy, but perhaps also even more importantly, patients in the early posttransplantation period.


- This systematic review highlights the scarcity of data that surrounds the management of chronic allograft nephropathy, and the lack of consensus on how to best approach this complication. Several strategies are reviewed with a focus on immunosuppressant management.
- Potential withdrawal of CNI can lead to better long-term graft survival but more studies need to be completed


- This review details how acute rejection, donor age, new onset diabetes after transplant, hyperlipidemia, hypertension, viral infections, drug toxicity and HLA antibodies contribute to the pathogenesis of chronic allograft nephropathy.


- This prospective study details the progression of CAN based in type 1 diabetic patients having received simultaneous kidney-pancreas transplantation. Biopsy samples were collected for 10 years on a per-protocol based approach.
- 2 stage treatment may be preferable in optimizing therapy to prevent CAN
  - Early stage: maximize calcineurin inhibitor to minimize early immunologic injury
  - Late stage: non-nephrotoxic immunosuppression can be implemented

Kidney transplant recipients receiving reduced TAC exposure were studied. Subclinical inflammation lesions at 3 months were found to be associated with IF/TA at 24 months. Conversion from TAC to SRL was associated with inferior renal function, higher incidence of IF/TA, and trends to higher incidence of DSA at 24 months.

At baseline, interstitial fibrosis and tubular atrophy occurred at 10% and at 24 months, rose to 57.6%.


Mean GFR higher was in tacrolimus group compared to other three groups; rate of biopsy-proven acute rejection was lower in tacrolimus group compared to other three groups; allograft survival was highest in tacrolimus group; serious adverse events were more common in sirolimus group.


Additional follow-up for 2 more years observationally after ELITE-Symphony trial standard. Renal function remained stable, and overall rates of death, graft loss, and acute rejection were low. MMF + low-dose tacrolimus + steroids had highest GFR, highest graft survival rate, and least acute rejection versus the other groups (see ELITE-Symphony trial above), but difference was not significant. Patients commonly switched from sirolimus to tacrolimus secondary to adverse events.


Systematic review of 4 RCTs evaluating conversion from calcineurin inhibitors to mTOR inhibitors in heart transplant recipients. Patients who underwent conversion had a higher creatinine clearance and lower serum creatinine levels (p=0.02). These patients had significantly higher occurrence of adverse events, including skin diseases, GI side effects, bone marrow suppression, and infections. There was no significant difference between groups in graft rejection.

The risk and benefits must be assessed for each patient when considering the switch between CNI to mTORi

There was improvement in renal function but had more adverse events specific to mTORi


This RCT included sequential randomizations between alemtuzumab and basiliximab induction, and between tacrolimus and sirolimus maintenance therapy at 6 months post-kidney transplant. Allocation to sirolimus had no significant effect on GFR at 18 months. Biopsy-proven acute rejection and serious infections (opportunistic infections or requiring hospitalizations) were significantly more common among patients in the sirolimus group.

Only half of the sirolimus group were taking their medication at 18 months after randomization.

This review article provides an overview of the association of nonadherence, antibody-mediated injury, disease recurrence, and BK nephropathy to chronic allograft nephropathy. Strategies to manage patients experiencing CAN are also included in this article.

- Potential strategies to minimize CAN are CNI minimization, better preservation of allograft after retrieval, use of protocol biopsies, active nonadherence screening, measurement of DSA post-transplant, HTN, HLD, and hyperglycemia management


- Updates from the 2017 Banff Conference for Allograft Pathology regarding diagnostics of chronic T-cell mediated rejection, inflammation in interstitial fibrosis and tubular atrophy, and antibody-mediated rejection


- Assessed peripheral blood for CD4+CD25+FOXP3+ regulatory T cell (Treg) levels in patients with chronic allograft nephropathy (CAN) 1 year after kidney transplantation
- Found low frequency of Tregs in peripheral blood from renal transplant patients with CAN suggests unfavorable prognosis for allograft immune tolerance

8.7. Hemolytic Uremic Syndrome (HUS)/Thrombotic Thrombocytopenic Purpura (TTP)


- This article provides a review of the etiology, pathology and treatments for TTP and aHUS in non-transplant patients.
- TTP and aHUS are chronic diseases that present with thrombocytopenia and microangiopathic hemolysis but have different pathology and pathogenesis and thus require different therapeutic approaches


- This review highlights the risk of recurrence of aHUS following kidney transplantation and discusses the roles of plasma exchange and eculizumab therapy to prevent recurrence.
- Patients with specific genetic abnormalities (CFH, CFI, C3, CFB) of aHUS will most likely need post-transplant eculizumab prophylaxis


- This reviews the pathology of aHUS, role of complement and genetic abnormalities contributing to aHUS in non-transplant patients. It also reviews extrarenal manifestations. Lastly, the role of liver-kidney transplantation for the syndrome and de novo aHUS after renal transplantation are addressed.


- This case report details the natural progression of TMA in a tacrolimus-treated patient and provides a brief narrative review of the history of TMA in transplantation.
- This case report provides supporting evidence that TTP can be associated with everolimus use in a sirolimus-conversion kidney transplant recipient.

- This retrospective case series identified lung transplant patients who experienced aHUS post-transplant in an mTOR- and CNI-combination regimen. Risk factors are also discussed.

- These 2 case reports highlight the potential importance of macrolide-tacrolimus drug-drug interaction leading to increased peak tacrolimus levels. This resulted in aHUS in lung transplant recipients.

- This review article discusses the potential advantages and mechanisms surrounding simultaneous liver-kidney transplantation to cure aHUS and decrease risk of recurrence.

- This review discusses transplant-specific incidence, pathophysiology, treatment and outcomes of TMA in SOT and BMT.

- This case report, followed by a review of 15 previous cases of tacrolimus-associated HUS, describes prevalence, time to onset, and outcome of the condition.

- This case report discusses a patient who received a kidney transplant secondary to aHUS. This patient received eculizumab weekly for one-month post-transplant, and the patient completed one year of follow-up with an uneventful post-transplant course.

- This case report details the course of a highly-sensitized renal transplant recipient with pretransplant DSA successfully converted from tacrolimus to belatacept within 1 week of transplant, secondary to the diagnosis of CNI-induced de novo HUS.

This case series describes 17 patients who underwent living donor kidney transplantation and received eculizumab prophylaxis due to documented post transplantation recurrent thrombotic microangiopathy. One patient had aHUS recurrence 68 days post-transplant, which was successfully treated with eculizumab. 3 patients were treated for rejection, and 2 patients developed BK nephropathy.


This review highlights recent progress in the pathogenesis, diagnosis, and current and potential novel therapies for hereditary and acquired TTP.